WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF ...

Sartorius Stedim Biotech (SSB) said today it will integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion ...

We think that for Repligen – we’ve been very successful as a company because we’ve been able to get high impact products launched into the marketplace, whether it’s OPUS, whether it’s ATF technology, ...

One-Time Therapeutics Player Bets Future on Working as Supplier to Bioprocess Companies Repligen, once a strongly focused therapeutics firm, has transformed itself into a bioprocess products company ...

What: After reporting third quarter financial results, updating investors on its outlook, and receiving a Wall Street downgrade, shares in Repligen Corporation tumbled by nearly 20% today. So what: In ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, ...

The bioprocessing leader's business looks solid, but here's one major risk for Repligen. Despite this solid rebound, risks remain for Repligen. One threat in particular holds the biggest potential to ...

On Tuesday, 18 November 2025, Repligen Corporation (NASDAQ:RGEN) presented at the Jefferies London Healthcare Conference 2025, showcasing robust growth and strategic initiatives. CEO Olivier Loeillot ...

Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Customers experience optimized facility equipment ...

A Wall Street downgrade offsets otherwise strong third quarter results and full year guidance. So what: In the third quarter, sales at Repligen climbed 31% to $19.8 million, bringing sales through the ...